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Abstract
Celiac disease (CD) affects approximately 1% of the population in Europe and 
North America, but the number of patients currently undiagnosed is estimated 
to be far higher than that of diagnosed cases owing to the presence of prevalent 
forms with nonspecific symptoms. The toxicity of gliadin in children with CD is not 
destroyed through digestion with gastropancreatic enzymes. An innate immunity 
to gliadin plays a key role in the development of CD. Autophagy, a physiological 
catabolic process, plays also a crucial role in the pathogenesis of several inflam-
matory diseases. Recent studies have described functional involvement of the 
regulation of autophagy within a pediatric CD cohort. Furthermore, the contribu-
tion of autophagy has been highlighted in the degradation and in the reduction of 
extracellular release of gliadin peptides, thus suggesting novel molecular targets to 
counteract gliadin-induced toxicity in CD.
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1. State of the art
Celiac disease (CD) is an immune-mediated disorder triggered by gluten inges-
tion in genetically susceptible subjects. About 1% of the European and North 
American population are affected, but the number of CD cases currently undiag-
nosed is suspected to be far superior to known cases due to the prevalence of forms 
with nonspecific symptoms. An increasing incidence of CD has been observed in 
developing countries, possibly due to westernization of the local diet, changes in 
wheat production/preparation, and increasing simplicity of diagnostic techniques. 
The principal determinant of genetic susceptibility to CD is the major histocompat-
ibility class II HLA molecules. The HLA-DQ2 haplotype is expressed in the majority 
of patients with CD, whereas the HLA-DQ8 haplotype is expressed only in a minor-
ity of patients. However, although the presence of the DQ2 and DQ8 haplotypes is a 
necessary condition, it is not sufficient for the development of CD. In point of fact, 
only 10% of people with a genetic predisposition goes on to develop CD.
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Gluten is a protein complex rich in proline and glutamine and is found in wheat, 
rye, and barley. The term gluten refers to a group of prolamins of wheat (gliadin and 
glutenin). Other prolamins are found in rye (secalin) and barley (hordein) and are 
genetically similar to each other.
It is particularly interesting that maize, while containing prolamins, causes no 
mucosal damage in celiac patients, most likely because a different phylogenetic evolu-
tion of maize prolamins makes its consumption safe for celiac subjects and not toxic.
Gluten is poorly digested in the human intestine regardless of the presence of 
celiac disease. Its oligopeptides cross the intestinal mucosa and reach the submu-
cosa where they are deamidated by transglutaminase type 2 (tTG2). Deamidation 
promotes high affinity binding with HLA DQ2 and DQ8 expressed on the surface 
of T lymphocytes. In celiac patients, this process triggers an inflammatory and 
immune-mediated response, typical of the disease. T lymphocytes recognize the 
HLA complex and release various cytokines including IL-15 and IFN-γ. These 
molecules induce the activation and clonal expansion of B cells which produce 
antibodies against gluten as well as autoantibodies against tTG2. Other cytokines 
stimulate fibroblasts and inflammatory cells to secrete matrix metalloproteinases 
with consequent tissue remodeling and further release of tTG2 in the extracellular 
compartment. At the same time, there is an increase in intraepithelial lymphocytes 
with cytolytic activity which determines epithelial damage.
The typical histological lesions of celiac disease are villous atrophy, intraepi-
thelial lymphocytosis, and crypt hyperplasia. Villous atrophy consists of decreased 
villous height and alteration of normal crypt/villous ratio (3:1) until total disap-
pearance of villi. Intraepithelial lymphocytosis is defined as a number of intraepi-
thelial lymphocyte (IEL) greater than 30 per 100 enterocytes. Crypt hyperplasia 
is the extension of the regenerative epithelial crypts associated with changes in the 
presence of more than one mitosis per crypt.
These elementary lesions associated with celiac disease are identified through 
duodenal biopsies from endoscopic evaluation. Multiple biopsies of the duodenum 
(at least one biopsy of the bulb and four of the distal part of the duodenum) are 
required to make a diagnosis as elementary lesions are not exclusive and frequently 
may be patchy [1].
In children, adding biopsies of the bulb increases diagnostic reliability, owing to 
the fact that in 10% of pediatric patients, villous atrophy is exclusively located in the 
duodenal bulb [2].
Histological changes can be classified according to the Marsh classification 
which identifies three entities: (1) type 1 or infiltrative lesions (normal villous and 
crypt architecture, normal villous/crypt ratio, and an increased number of intraepi-
thelial lymphocytes); (2) type 2 or hyperplastic lesion (normal villous architecture, 
hyperplasia of the glandular element with an increased number of mitoses, and 
increased intraepithelial lymphocytes); and (3) type 3 or destructive lesion (vary-
ing degrees of villous atrophy associated with hyperplasia of the glandular crypt 
and increased intraepithelial lymphocytes). Oberhuber et al. [3] proposed a differ-
ent classification dividing the Marsh type 3 lesion into three subgroups according to 
the severity of villous atrophy: (3a) mild villous atrophy and pathological increase 
of IELs; (3b) moderate villous atrophy and pathological increase of IELs; and (3c) 
total villous atrophy and pathological increase of IELs.
Diagnosis of CD is based not only on histology but also on the presence of 
specific serological markers which should be performed in patients on a gluten-
containing diet.
Anti-tTG2 is circulating, gluten-dependent, autoantibodies that target transglu-
taminase 2, the principal self-antigen involved in pathogenesis of CD. IgA anti-tTG2 
has high sensitivity (97%) and specificity (91%) and is deemed the single most 
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reliable test for detection of CD in primary care in cases of clinical suspicion or as 
a screening test in relatives of celiac patients or in people with an increased risk of 
developing CD. In comparison with the anti-endomysial antibody, the anti-tTG2 IgA 
assay has greater sensitivity and reproducibility. It is important to remember that IgA 
deficiency is more common among celiac patients than in the general population; 
therefore, in cases of low serum IgA levels, IgG class anti-tTG2 should be evaluated.
Anti-endomysial antibodies (EMA) are directed against the intermyofibril 
substance of smooth muscle, which may correspond to either a reticulin-like 
structure or a surface component of smooth muscle fibrils. These are detected by 
indirect immunofluorescence on monkey esophagus cells and on human umbilical 
cord cells as a substrate. The EMA assay specificity is high (100%), but it is also IgA-
based and the EMA IgG assay is not widely available. Anti-endomysial antibodies 
are considered a confirmatory assay and should be used only in cases of borderline 
positive or possibly false positive results for anti-tTG2.
Testing for antibodies directed against native gliadin is no longer recommended. 
However, antibodies against synthetic deamidated IgG class gliadin peptides (anti-
DPG) have a diagnostic role in cases of IgA deficiency.
Histological evaluation and serological markers are important for diagnosis but 
also for testing efficacy of alternative therapies for celiac disease, as mentioned below.
Currently, the only effective treatment for celiac disease is a strict gluten-free 
diet (GFD). The aim of dietary regimen is recovery of intestinal damage (usually 
within 24 months), disappearance of serological markers, and resolution of symp-
toms, when present. Moreover, a GFD improves nutritional parameters including 
body mass index and bone mineral density.
Celiac patients should avoid all products containing wheat, barley, and rye for 
life. Complete elimination of gluten is very difficult, especially due to contamina-
tion of other foods with traces of gluten.
Strict avoidance of gluten is demanding especially in Mediterranean countries 
where gluten ingestion in normal diet is high as well as in adolescence and in 
asymptomatic children diagnosed by screening. Therefore, CD subjects should be 
monitored annually for adherence to the GFD. Verification of the disappearance of 
the specific antibodies is important during follow-up.
The definition “gluten-free” is reserved for foods having less than 20 parts per 
million of gluten. The lowest quantity of gluten known to be responsible for muco-
sal damage ranges from 10 to 50 mg per day. A gluten intake of less than 10 mg per 
day is unlikely to cause mucosal damage.
Nevertheless, some patients may be more sensitive than others are to gluten 
exposure. Therefore, compliance to GFD should be strict and lifelong.
The gluten-free diet has numerous difficulties; a significant lifestyle change 
is required by patients, and it may be challenging especially in Western countries 
where gluten is contained in a lot of foods.
Furthermore, gluten-free products are more expensive [4] and are known to 
have poor palatability and high fat content.
Hypothetical gluten exposure in restaurants may also be a source of anxiety for 
celiac patients [5].
It is extremely important that patients know potential hidden sources of gluten 
and obtain precise information about gluten-free substitute and their fiber and 
nutrient content. Celiac patients should have high-fiber diets and frequently need 
supplementation of iron, folic acid, vitamin B12, and vitamin D. It may be very 
useful to refer patients to a dietitian at the time of diagnosis.
Serological markers are used to assess adhesion to gluten-free diet and its effi-
cacy. First of all, in a patient with persistent symptoms, despite a gluten-free diet, 
it is mandatory to verify strictly compliance to GFD and in particular to investigate 
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the possibility of inadvertent gluten exposure. Second, it is important to exclude 
other causes of persistent symptoms. It is necessary to underline the hypothetic 
presence of alternative diagnosis (i.e., lactose or fructose intolerance, irritable 
bowel syndrome, microscopic colitis, pancreatic insufficiency, and small intestinal 
bacterial overgrowth). Another reason for the recurrence of clinical manifestations 
is refractory celiac disease, whereby CD patients present symptoms of malabsorp-
tion and villous atrophy despite a GFD for more than 12 months. In the primary 
form, there is no initial response to a diet, while in the secondary one, a relapse 
occurs after an initial response to a GFD. Patients with refractory CD are at risk of 
developing enteropathy-associated T cell lymphomas.
2. The autophagy process
Eukaryotic cells digest their cytoplasmic content through different processes 
that come under the general term autophagy (from the Greek words auto mean-
ing “self” and paghein meaning “to eat”). Autophagy includes different forms of 
digestive pathways such as macroautophagy, microautophagy, chaperone-mediated 
autophagy, and noncanonical autophagy. Generally, the term autophagy refers 
to macroautophagy, and this process depends on specialized autophagy-related 
proteins (ATGs) to digest different targets, such as organelles, large aggregates of 
proteins, and microorganisms. Autophagy also plays a key role in direct microor-
ganisms and virus clearance, in the control of inflammation through the inhibition 
of inflammasome, in antigen presentation, in regulating T cell homeostasis, and 
the secretion of immune mediators [6]. It is worth nothing that autophagy impair-
ment plays a crucial role in several diseases, in particular proteopathies, such as 
Parkinson’s [7] and Huntington’s disease [8].
As analytically described by Codogno et al. [9], there are four types of autophagy:
• Macroautophagy: organelles or other cargos (proteins, lipids, or nucleic acids) 
are sequestered in the autophagosome, a double-membrane vesicle, and 
delivered to the lysosome for degradation.
• Microautophagy: small cytosolic materials are degraded after their engulfment 
in lysosomes through membrane invagination processes.
• Chaperone-mediated autophagy: proteins with the specific KFERQ target 
sequence are recognized by chaperone Hsc70 protein and then degraded by 
lysosomes action.
• Noncanonical autophagy: under specific circumstances autophagosome forma-
tion in macroautophagy can bypass the canonical steps. To date two nonca-
nonical pathways have been described: Beclin-1-independent autophagy and a 
pathway that bypasses the action of specific autophagy-related proteins such as 
ATG5, ATG7, and LC3.
To date, several autophagy-related genes (ATGs) have been described and exert 
a finely coordinated function at different stages of the pathway. It is widely accepted 
that autophagy consists of six sequential steps: (1) initiation; (2) nucleation or 
phagophore formation; (3) ATG5-ATG12 conjugation, interaction with ATG16L, 
and multimerization at the phagophore; (4) LC3 processing and insertion into the 
nascent autophagosome; (5) capture of random/selective targets for degradation; 
and (6) fusion of the autophagosome with the lysosome.
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3. Autophagy and autoimmune diseases
Autophagy plays a crucial role in the pathogenesis of several autoimmune diseases. 
In particular, in Crohn’s disease, an inflammatory bowel disease is caused by a com-
bination of environmental, immune, and bacterial factors in genetically susceptible 
individuals. It has been demonstrated that genetic polymorphisms in the ATG16L 
and IRGM autophagy-related genes lead to a strong predisposition for the develop-
ment of Crohn’s disease [10]. Despite this significant association, the role played by 
the ATG16L protein in the disease pathogenesis is still under debate. In particular, the 
ATG16L protein is known to suppress the inflammatory process, as demonstrated in 
Atg16L-deficient mice, which were find to be highly susceptible to colitis induced by 
dextran sulfate sodium. Subsequently the symptoms developed by these mice were 
effectively treated with injections of anti-IL-1β and IL-18 antibodies [11]. Recently, 
nucleotide polymorphisms within the key regulatory autophagy gene ULK1 have 
been shown to increase susceptibility to Crohn’s disease, thus demonstrating that 
autophagy might contribute to the pathogenesis of this disease [12]. Similarly, the 
ATG5 protein, another essential component of the autophagic machinery, is impli-
cated in the development of systemic lupus erythematosus (SLE), multiple sclerosis 
(MS), and rheumatoid arthritis (RA). SLE is an autoimmune disease in which the 
patient’s immune system attacks healthy tissues. Different single nucleotide poly-
morphisms (SNPs), identified near and within the ATG5 locus, are associated with 
SLE initiation and/or development, although the pathogenetic mechanisms involved 
are still unknown. In another study, it was demonstrated that T cells in SLE patients 
are autoreactive and autophagy promotes their survival and contributes to their 
persistence in autoimmune conditions [13]. MS is a demyelinating disease that affects 
the brain and the spinal cord. Changes in the expression of the ATG5 protein cor-
relates also with immune-mediated myelin injury in MS-derived mice and in affected 
patients. Specifically, ATG5 is overexpressed in circulating T cells of relapsing–remit-
ting MS patients compared with healthy controls. ATG5 altered expression seems 
to extend T cell survival and proliferation during active disease; moreover, ATG5 
expression profiles correlate with the severity of the disease in mice models [14]. In 
RA, anti-citrullinated protein antibodies are the most powerful biomarkers in the 
diagnosis of this disease. During inflammation, the arginine residues of self-proteins 
are converted to citrulline (a nonessential alpha amino acid) by the peptidylarginine 
deiminase enzyme, in a process known as citrullination, thus leading to an altered 
immune response. Presentation of these peptides is blocked after treatment with 
3-methyladenine, an autophagy modulator drug, or by reducing ATG5 protein expres-
sion, confirming a key role of autophagy in RA pathogenesis [15].
The clinical spectrum of celiac disease is broad, and often it may be not so easy 
to discern between poor compliance, difficult acceptance of therapy, or presence of 
disease complications.
It is important to emphasize experimental therapies, in terms of alternative 
treatment (versus gluten-free diet) or GFD adjuvant.
Recent advances in the “non-dietary” treatment of CD include engineering 
gluten-free grains, degrading immunodominant gliadin peptides, decreasing intes-
tinal permeability, and inducing oral tolerance to gluten with a therapeutic vaccine.
4. Non-dietary therapies
As outlined above, there are many reasons behind the need to identify new 
therapeutic options for celiac disease, especially non-dietary therapies. The purpose 
is to offer a better quality of life to celiac patients.
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Over the years several studies regarding alternative therapies have been conducted.
The aim of experimental research is to find a drug that reduces bowel inflam-
mation despite gluten exposure. Evaluation of mucosal damage is the best way to 
verify the efficacy of alternative drugs, but it is an invasive procedure and especially 
distressing for children. Noninvasive markers of efficacy could be serological 
normalization (using tTG-IgA title) or the improvement of clinical symptoms.
In celiac patients exposed to gluten, increased intestinal permeability has been 
observed and is due to defects in tight junctions, which are structures involved 
in regulating the passage through the paracellular space. Increased permeability 
determines the passage of gluten peptides, which reach lamina propria and stimu-
late inflammatory response [16].
Larazotide acetate is an oral peptide derived from the zonula occludens toxin 
secreted by Vibrio cholerae. It is believed to be involved in the modulation of tight 
junctions, consequently preventing gliadin passage through the epithelial barrier. 
Numerous trials have been conducted to verify the efficacy of larazotide. It has been 
shown to reduce symptoms in patients on a gluten-free diet [17].
Significant effects of larazotide on serological markers have not been demon-
strated, and mucosal damage healing does not appear to be the focus of the evalua-
tion of this drug’s efficacy.
Another target of alternative drug is the degradation of toxic gluten peptides making 
them non-immunogenic. Several endopeptidases have been studied for this purpose.
AN-PEP (Aspergillus niger prolyl endoprotease) is an Aspergillus niger-derived 
endopeptidase which was studied in a randomized trial where celiac patients were 
divided into two groups: one of which received AN-PEP and the other a placebo. 
All patients followed a diet with gluten exposure (7 g of gluten daily) for 2 weeks. 
AN-PEP appeared to be well-tolerated, but no difference as regards mucosal damage 
was observed between two groups [18].
ALV003 is a combination of two types of glutamine-specific endoprotease, 
EP-B2 from barley and a prolyl endopeptidase (SC PEP from Sphingomonas 
 capsulata); it is active at gastric pH and able to detoxify gluten [19].
It has been observed that ALV003 can prevent mucosal damage, secondary to 
gluten exposure, in celiac patients with moderate gluten consumption [20].
Over the years, the emerging role of gut microbiota in different diseases has been 
noted. Variations in the composition of microbiota could play a causative role in the 
pathogenesis of inflammatory and autoimmune diseases.
The microbial community is composed of more than 1000 species of microbes 
which exert various functions on the immune system, including protecting the 
body against pathogens, harvesting nutrients and energy from diet, and fermenting 
nondigestible carbohydrates.
A specific role of intestinal microbiota in the development of celiac disease has 
been suggested.
Frequent infectious diseases and consequent antibiotic treatments (with second-
ary effects on the intestinal microbiota) have also been associated with the onset of 
celiac disease in genetically susceptible infants [21].
In celiac patients, a prevalence of Bacteroides spp. has been found [22] along with 
a reduction in numbers of Bifidobacterium species [23].
Furthermore, regardless of GFD, celiac patients presented less variability of Bacteroides 
species in biopsy samples of the duodenal microbiota in comparison with controls [24].
Several studies regarding the association of Bifidobacterium and celiac disease 
have been conducted. Bifidobacterium infantis and Bifidobacterium lactis were found 
to contrast the increase of permeability, secondary to gluten ingestion, in the celiac 
bowel. They are also thought to play a role as downregulators of immune response 
in celiac patients [25–27].
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Therefore, a therapeutic function of Bifidobacteria may be considered and it 
could be investigated through further studies.
BL-7010 is an orally available polymer with a high affinity for gliadins. Polymeric 
binders are used to reduce the intestinal absorption of endogenous or exogenous 
molecules.
BL-7010 sequesters gliadin and masks it from enzymatic degradation. Through 
this mechanism, it is thought to prevent the formation of immunogenic peptides 
that trigger the immune system.
It is chemically stable at a wide pH range, is non-biodegradable, and is water-
soluble. It exerts its function locally in the gastrointestinal tract and is not absorbed 
systemically; therefore, it has a very good safety profile as was demonstrated in 
preclinical studies. In vitro and in mouse models have shown that BL-7010 is able to 
bind gliadin and to prevent barrier dysfunction, changes in IELs, and villous/crypt 
ratios induced by gliadin [28].
Another therapeutic target identified in recent years is a vaccine called Nexvax2. 
The aim of this drug is to restore immune tolerance to gluten using peptide-based 
immunotherapy to induce T cells to make a regulatory response. Murine models 
were used for the study, and three immunogenic peptides have been identified. 
These peptides elicit an immune response in patients with celiac disease who carry 
the HLA-DQ2 immune recognition gene. Tolerance is based on reduction of CD4 
T cell proliferation, decreasing IL-2 and IFN-γ levels and promoting expression 
of T cells with regulatory functions. It was reported that patients treated with the 
vaccine (especially with high doses) presented gastrointestinal side effects similar 
to celiac symptoms. This finding corroborates the hypothesis that the vaccine has a 
similar action to gluten ingestion as regards intestinal immunity [29].
Another attempt at immuno-modulation was made using CCX282-B an antago-
nist of the CCR9 chemokine receptor. Increased blood levels of T cells expressing 
CCR9 have been found in celiac patients. It is thought that CCX282-B may prevent T 
cell migration from the blood to the intestinal mucosa. Unfortunately the results of 
this study are not yet available.
A further consideration is the hygiene hypothesis, whereby excess hygiene is 
thought to trigger the inflammatory process through immune imbalance resulting in 
autoimmune disorders. The effect of helminth infections on immunity has also been 
studied, in particular their role in celiac disease and in inflammatory bowel disease.
Interestingly, it has been reported that the Necator americanus species of hook-
worm enabled individuals with celiac disease to tolerate escalating challenges with 
dietary gluten [30]. The exact mechanism responsible for tolerance is not known, 
and further studies are expected.
As previously described, reasons justifying the search for an alternative therapies 
for celiac disease are numerous, and several studies have been conducted to assess 
their efficacy. The aim is to identify a new drug and, at the same time, to define new 
hypothetical therapeutic targets to improve celiac patients’ quality of life.
Over the years we have studied the autophagy process. Our results have high-
lighted the possible contribution of this process to the degradation and the reduc-
tion of extracellular release of gliadin peptides and suggest novel molecular targets 
to counteract gliadin-induced toxicity in CD.
5. Autophagy and celiac disease
The primary link between autophagy and celiac disease is that autophagy is 
conventionally described as a catabolic pathway where the cytoplasmic material 
sequestered by autophagosomes is degraded. Therefore, the exogenous gliadin 
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peptides content might be a potential target of the autophagy clearance process. 
The autophagy escape, on the other hand, might specifically lead to MHC antigen 
presentation by dendritic cells or to other unspecific exocytic/endocytic processes 
between different cells.
Autophagy is known to modulate two crucial aspects of the adaptive immune 
response involved in the pathological context of the celiac condition: it can enhance 
priming of CD4+ T cell responses, but at the same time, by allowing the presentation 
of self-peptides, it may also regulate the establishment of peripheral T cell tolerance 
[31]. Importantly, antigen presentation by MHC class I or II proteins is dependent on 
the activity of the proteasome or the endocytic/phagocytic system, respectively, and 
therefore associated with the functionality of the autophagy process.
To date, however, only a few scientific publications have attempted to investigate 
the functional role of the autophagy process in celiac disease.
Weersma and colleagues [32] first reported the absence of association of IL23R 
and ATG16L1 mutations with celiac disease susceptibility, in contrast to that of 
Crohn’s disease. This result was subsequently confirmed independently by genetic 
analysis in a different cohort of celiac disease patients [33].
More recently, Rajaguru and colleagues [34] evaluated the expression of the LC3 
autophagy marker in duodenal biopsies of celiac patients at initial presentation and 
after 6 months of gluten-free diet, reporting a time-related reduction of LC3 expres-
sion in dendritic cells through immunohistochemical analysis. The authors concluded 
that the observed typical histological pathological hallmarks in duodenal biopsies were 
associated with a reduction in activated dendritic cells expressing autophagic proteins. 
This alteration within the autophagy executor organelles may well play an important 
role in the pathogenesis of autoimmune disorders like celiac disease.
Comincini and collaborators [35] have recently tackled a different question 
regarding celiac disease, i.e., the possibility to identify novel molecular markers in 
order to increase the sensitivity and specificity in the diagnosis of pediatric celiac 
disease patients. To this end, the expression levels of two key autophagy executor 
genes (ATG7 and BECN1) and their regulatory validated miRNAs (miR-17 and 
miR-30a, respectively) were analyzed by relative quantitative real-time PCR on a 
cohort of confirmed celiac patients compared to age-related controls, analyzing 
peripheral blood, and corresponding duodenal specimens. Among the investigated 
gene/miRNA targets, statistical analysis indicated the highest significant association 
as that of BECN1 expression profiles with the pathological status in the blood, while 
in intestinal biopsies, all the investigated sequences were positively associated with 
the celiac disease condition. The authors were also able to identify specific celiac/
control molecular subtypes based on specific genes and miRNA expression signa-
tures. Overall, the authors described novel molecular markers that might be useful 
in increasing the accuracy in CD diagnosis and in molecular-based stratification of 
the patients, further reinforcing the functional involvement of the regulation of the 
autophagy process in digestive and autoimmune-related disorders such as CD.
In the latest PubMed contribution, Manai and collaborators [36] reported 
that in Caco-2 cells, a widely used in vitro model for celiac disease studies, 
the administration of enzymatically digested gliadin (PT-gliadin) peptides 
significantly reduced the expression of the LC3-II autophagy-related marker. 
Furthermore, electron and fluorescent microscope analysis suggested a com-
promised function of the autophagosome apparatus. The improvement of the 
dysregulated autophagy process, along with a reduction of PT-gliadin toxicity, 
was achieved by means of a starvation induction protocol and by 3-methylade-
nine administration, while rapamycin, a well-known autophagy inducer, did not 
produce significant improvement in the clearance of extra- and intracellular flu-
orescent PT-gliadin amounts. Importantly, these results highlighted the possible 
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contribution of the autophagy process to the degradation and the reduction of 
extracellular release of gliadin peptides and suggest novel molecular targets to 
counteract gliadin-induced toxicity in celiac disease. A schematized summary 
of the autophagy-modulation strategy to counteract the gluten-derived cellular 
toxicity is illustrated in Figure 1.
6. Concluding remarks
Celiac disease is an increasingly complex disease, with a well-established genetic 
background but with a plethora of molecular/cellular actors involved. Despite this 
emerging complexity, the cellular uptake of the digested gliadin components and 
their ultimate fate is the key determinant for this disease. Once within a cell, gliadin 
peptides, as with any exogenous components, undergo different catabolic processes, 
including the relatively low-energy consumption processes such as exocytosis. In 
this scenario, autophagy protein turnover might represent a pro-survival process to 
counteract a surge in potentially toxic gliadin. However, for reasons still unknown, the 
autophagy process seems to be impaired in the celiac condition: as a result, gliadin is 
easily internalized in different types of cells, but no marked signs of a prominent deg-
radation are reported. On the other hand, more and more is being learned about the 
process of autophagy and its molecular players, and, consequently, a relatively large 
number of molecular and pharmacological modulators are being put on the market 
and assayed in clinical trials for different pathologies. Therefore, once the alterations 
of the steady-state status of the autophagy process are clarified by comparing physi-
ological to celiac pathological conditions, one could realistically hope to counteract 
gliadin toxicity by improving its catabolism within the cells, bearing in mind however 
Figure 1. 
Gluten degradation by autophagy process. Gluten digested peptides (1) can be internalized into different 
cell types, including human dendritic cells. These peptides form relatively large intracellular aggregates, 
partially resistant to intracellular catabolic process, and they can also be released to other surrounding cells by 
exocytic processes. The discussed approach, (2) based on the autophagy activation using drugs (rapamycyn, 
chloroquine, etc.) or by means of starvation induction, (3) leads to the fusion of autophagosomes and lysosomes 
to produce autophago-lysosomes, able to digest the gluten digested peptides. (4) this intracellular digestion 
produces a reduction of the exocytosis of the gluten peptides, and, mostly, (5) it might reduce the gluten-peptide 
presentation by MHC-II molecules (HLA-DQ2.5) and therefore the pathological activation of T cell in the 
celiac disease.
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that the exacerbation of the fine autophagy intracellular balance might also lead to 
other, even more complex pathological conditions such as cancers.
This article focuses on the results of researches carried out by authors in the field 
of celiac disease.
It is of the upmost importance to investigate new therapeutic options for celiac 
patients, especially non-dietary therapies, in order to improve their quality of life.
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